Document:

EX-10.17

 Exhibit 10.17 
 KANSAS BIOSCIENCE RESEARCH AND DEVELOPMENT (R&D) VOUCHER PROGRAM GRANT AGREEMENT 
 This Research and Development Voucher Grant Agreement (“Agreement”) dated as March 6, 2012 (the “Effective Date”) is by and between the Kansas Bioscience Authority,
10900 S. Clay Blair Blvd., Olathe, Kansas 66061 (the “KBA”) and Aratana Therapeutics, Inc., 1901 Olathe Blvd., Kansas City, KS 66103 (the “Grantee”), collectively the “Parties.” 

WHEREAS, Grantee has requested a grant from the KBA for the purposes described herein; 

WHEREAS, the KBA has the power to provide the grant, as defined below, under the Kansas Bioscience Authority Act, K.S.A. 74-99b01,
et seq., as amended from time to time (“KBA Act”); 
 WHEREAS, in accordance with the terms of the KBA Act and
the policies and procedures of the KBA, the Investment Committee on February 20, 2012 has recommended and on March 6, 2012 the Board of Directors has approved funding to Grantee in the amount up to One Million Three Hundred Thirty Three
Thousand Three Hundred and Thirty Three Dollars ($1,333,333) over an estimated two year period (the “Grant”) pursuant to the Kansas Bioscience R&D Voucher Program; 

WHEREAS, in accordance with the terms of the KBA Act and the policies and procedures of the KBA, Grantee acknowledges that under
no circumstances does the KBA solicit or accept donations in return for KBA funds; 
 WHEREAS, the Parties are entering
into this Agreement to set forth the terms and conditions of the Grant and acknowledge that all terms and conditions are subject to funding restrictions imposed upon the KBA by the State of Kansas and may require an award reduction or termination of
this Agreement. 
 NOW, THEREFORE, the above recitals being made a part of this Agreement, the KBA and Grantee
agree as follows: 
 1. Project. The KBA approved a Grant in the amount up to $1,333,333 to Grantee. Grantee agrees to use all
of the Grant exclusively to support the pre-formulation, formulation, manufacture and pivotal studies of its first two companion animal development programs. Aratana will conduct work with Kansas companies to advance these programs, spending an
estimated total of $4.0 million in Kansas (the “Project”). 
 KBA will reimburse 33% of the Grantee’s quarterly
expenses that are directly related to the Project activities up to the maximum funding amount of $1,333,333. The research partner(s) authorized to be paid using KBA funds are Argenta, AlcheraBio, Xenometrics and KCAS. Additional authorized Kansas
research partners may be added by Grantee only upon written approval by KBA. KBA will make payments based on Grantee’s acceptable completion of the terms of each milestone listed in Section 3, as determined by the sole judgment of the KBA
and may make payments directly to the research partner(s) if requested. This includes verification that Grantee has contributed its 67% portion to the Project and that any applicable University

  
 1 

 
research partner(s) have contributed at least its 20% portion of KBA funds to the Project. The applicable University research partner’s Indirect costs (Facilities and Administration) cannot
be covered using KBA funds. In addition, KBA funds cannot be used for rent, capital costs, or utilities. 
 Grantee may not use
any portion of the Grant, including any interest earned thereon, for any other purpose without the prior written approval of the KBA. At no time will the Grantee use any portion of the Grant for a purpose inconsistent with the KBA Act. 

2. Reports. During the term of the Grant, and for a ten-year period after the final Grant payment made by the KBA under this
Agreement, Grantee will provide a written annual report to the KBA regarding the Project and Grantee’s use of the Grant. The KBA will provide the Grantee a reporting form and require the Grantee to complete it at least annually and within 30
days from the request date. Grantee must complete the reporting form to the satisfaction of the KBA. The report may include, but not be limited to, the following as they relate to this Grant: 

 

	•	 	 Full-time jobs created and jobs retained in the state of Kansas and total associated wages and average wage 

 

	•	 	 Part-time jobs created and retained in the state of Kansas and total associated wages and average wage 

 

	•	 	 Number of strategic partners 

  

	•	 	 Number of invention disclosures and of patents applied for and granted 

 

	•	 	 Annual research funding 

  

	•	 	 SBIR/Federal technology development financing 

  

	•	 	 Capital expenditures (purchase or rehabilitation of land, building and equipment) 

 

	•	 	 New start-up companies created in the state of Kansas 

 

	•	 	 Number of commercial products or services and associated income 

 

	•	 	 Third party funding (cumulative equity investment) 

  

	 	•	 	 Venture capital 

  

	 	•	 	 Convertible debt 

  

	 	•	 	 Other investments (e.g. strategic partners) 

  

	•	 	 Indirect Outcomes 

  

	 	•	 	 Market capitalization 

  

	 	•	 	 Revenue from Kansas operations 

  

	 	•	 	 Net income from Kansas operations 

  

	 	•	 	 Income tax paid in Kansas 

  

	 	•	 	 Property tax paid in Kansas 

  

	 	•	 	 Total company revenue in the most recent fiscal year 

  

	 	•	 	 Total company revenue in the previous fiscal year 

  

	 	•	 	 Total company net income 

 3. Milestones. If the Grant will be paid to Grantee in increments upon achievement by Grantee of specified milestones, Grantee will provide the Award Payment Request Form attached hereto as
Exhibit A; any supporting documentation; a clear statement of the objectives, tasks, and outcomes for each milestone associated with the payment request; and actual expenses against the approved budget attached hereto as Exhibit B.

  
 2 

 Grantee will report immediately in writing to the KBA each milestone achievement. KBA’s
Contract Administrator will review the request for payment and if deemed appropriate will process the payment request according to KBA policies and procedures. Payment will be made within 45 days of final approval by the KBA’s executive staff.

 The milestone schedule is as follows: 
  

									
	 Milestone
	  	  	  	  	  	 Milestone Description and Documentation:
	  	 KBA
Payment

	 1. Completion of Quarterly Project Activities

 
 (Expected Completion – July 2012)
	  	 a)
	  	Execution of R&D Voucher Grant Agreement between the KBA and Aratana.	  	33% of Project Expenditures in Kansas up to $1,333,333
	  	  
 b)
	  	  
 Copies of executed service agreements between Aratana
and Argenta, AlcheraBio, Xenometrics, KCAS.
	  
	  		  	  
 1)
	  	  
 If work is being conducted under a Master Agreement, provide a copy
of the Master Agreement and copies of the specific work orders for which Aratana is seeking reimbursement.
	  
	  	  
 c)
	  	  
 Quarterly Project Expenses
	  	
		  		  	  
 1)
	  	  
 Copies of research partner invoices and certification by an officer
of Aratana of payment. KBA will reimburse 33% of paid project expenses for work conducted in Kansas.
	  	
		  		  	  
 2)
	  	  
 Certification by Aratana that work subject to KBA reimbursement has
been conducted in Kansas.
	  	
		  	  
 d)
	  	  
 Summary report of Project results to date and
anticipated activities for the next quarter
	  	
				
	 Milestones 2 thru 8
  

Completion of Quarterly Project Activities
	  	a)	  	Quarterly Project Expenses	  	33% of Project Expenditures in Kansas up to $1,333,333
	  		  	  
 1)
	  	  
 Copies of research partner invoices and certification by an officer
of Aratana of payment. KBA will reimburse 33% of paid project expenses for work conducted in Kansas.
	  
	  		  	  
 2)
	  	  
 If work is being conducted under a Master Agreement, provide a copy
of the specific work orders for which Aratana is seeking reimbursement.
	  
					
		  		  	3)	  	Certification by Aratana that work subject to KBA reimbursement has been conducted in Kansas.	  	
				
		  	b)	  	Summary report of Project results to date and anticipated activities for the next quarter	  	
				
		  	c)	  	The Quarterly period for project expenses and activities will be as follows:	  	
				
		  		  	 Milestone 2 – July through September 2012
 Milestone 3 – October through December 2012
 Milestone 4 – January through March
2013
 Milestone 5 – April through June 2013
 Milestone 6 – July through September 2013
 Milestone 7 – October through December
2013
 Milestone 8 – January through March 2014
	  	
				
		  	d)	  	Payment of all Milestone Requests will be subject to submission of applicable annual Post-Award Reports as required by KBA Grant Agreement.	  	

  
 3 

									
		  	NOTE: The following will apply to specific Quarterly Milestone Payment Requests as indicated:	  	
				
		  	1.	  	With the Milestone # 4 Request, Aratana will submit a Work Plan and Budget for projects to take place over the next 12 months.	  	
				
		  	2.	  	With the Milestone # 8 Request, Aratana will submit a Final Project Report.	  	
				
		  	3.	  	If Aratana changes project partners, copies of executed Service Agreements must be provided before expenses will be reimbursed.	  	
		  		  		  	 NOT-TO-EXCEED TOTAL :
	  	$1,333,333

 4. Term. This Agreement will begin upon the Effective Date and will terminate
on the 10th anniversary of the final Grant payment.

 5. Use of Funds. Grantee agrees that the Grant will be used in accordance with the purpose submitted by Grantee as
part of its Grant request, as approved by the KBA. If the Grant is for a project that has milestones, each milestone’s Grant payment is contingent upon satisfactory progress and expenditure of funds as budgeted. All Grant payments are
contingent upon the KBA’s satisfaction with the reports submitted as required in Section 2 and adherence to the milestone schedule outline in Section 3. The KBA reserves the right to discontinue, modify, or withhold any payments to be
made under this Agreement, if the KBA determines that (a) Grantee has not fully complied with the material terms and conditions of this Agreement; (b) action is necessary to protect the purposes and objectives of the Project; or
(c) action is necessary to comply with any law or regulation applicable to Grantee, the KBA, the Project, or this Agreement. No action by the Grantee shall be in violation or frustration of the Kansas Economic Growth Act, the mission of the KBA
or any other applicable laws. Grantee shall perform or comply with all terms and provisions of this Agreement. If Grantee fails to comply and such failure is not cured within a timely manner from the date of receipt of notice of the existence and
nature of the failure or violation, then KBA may require a total or partial refund of any Grant payments made. 

Notwithstanding the foregoing, and at the election of the KBA, this Agreement may be terminated by KBA and Grantee may be required to
repay to the KBA the Grant in accordance with Kansas Statute Annotated 74-99b18 (attached hereto as Exhibit C) or upon the occurrence of any one of the following events: (a) Grantee initiates procedures to dissolve and wind up; or
(b) the Grantee ceases operation within the state of Kansas during the Term of this Agreement. KBA retains all rights afforded to it, as a creditor and otherwise, under the U.S. Bankruptcy code as amended from time to time. 

6. Confidentiality. Both parties agree that information marked “Proprietary” or “Confidential” related to this
Project will be kept confidential by the parties to the extent permitted by law. Notwithstanding the foregoing, Grantee acknowledges that the KBA is subject to the Kansas Open Records Act (“KORA”), and Grantee therefore agrees (a) to
act in accordance with any direction made by the KBA as required by KORA regarding open records, and (b) that the disclosure of any information related to the Project required under KORA does not constitute a breach of confidentiality or this
Agreement. KBA agrees to provide timely 

  
 4 

 
notification to the Grantee of any KORA request relating to the Project. This requirement of confidentiality does not pertain to the publication of research results in peer-reviewed journals or
publication of theses or dissertations. Additionally, acknowledgement of KBA funding or sponsorship in a factual statement is not prohibited by this clause. 
 7. Financial Statements. Grantee agrees to keep financial statements and other records in a manner satisfactory to the KBA to adequately account for the use of the Grant exclusively for the
Project’s purposes, and to make such financial statements and other records available to the KBA upon request. 
 8.
Furnishing of Information. Grantee agrees to supply the KBA with such information as the KBA requests, in its sole judgment, to establish the use of the Grant in furtherance of the Project. 

9. Reserved. 
 10. Media. 
 A. Acknowledgment of Support. The Grantee is
responsible for ensuring that KBA support is acknowledged as follows: 
  

	 	i.	In any publication by Grantee or publication in which Grantee has knowingly furnished information, whether in electronic or in paper form, of any material based on or
developed under this Project, by specifically stating that the Project is supported in part by funding from the Kansas Bioscience Authority, except that such acknowledgement is not required when research projects are 1) fully funded by an
organization other than KBA, or 2) the publication prohibits or does not provide for acknowledgement; and 

  

	 	ii.	Orally during all media interviews with Grantee’s employee when acting in their official capacities, including popular media such as radio, television and news
magazines, by specifically stating that the Project is supported by funding from the Kansas Bioscience Authority. 

B. News Releases. No formal news release concerning the Project shall be issued by Grantee without prior written coordination with
the KBA’s Director of Marketing and Communications or his or her designee. 
 C. Attendance at Events. Grantee must
make reasonable efforts to send representation to key events as requested by the KBA which may include Bioscience Day at the state capitol, the KBA annual meeting, and other such events. 

D. Disclaimer. The Grantee is responsible for ensuring that every publication of material by Grantee, whether in electronic or
paper form, based on or developed under the Project, except articles or papers appearing in scientific, technical or professional journals or comparable written presentations and communications, contains the following disclaimer: “Any opinions,
findings, conclusions and recommendations expressed in this material are those of the author or authors and do not necessarily reflect the views of the Kansas Bioscience Authority.” 

  
 5 

 E. Copies for KBA. The Grantee must provide the Contract Administrator with a copy of
every publication by Grantee of Project material based on or developed under this Grant, promptly after publication and in either electronic or in paper form. 
 11. Application Fees. Any and all fees associated with the Application will be assumed by Grantee and are not eligible for payment or reimbursement by the KBA. 

12. Assignability. This Agreement may not be assigned without the express written consent of the KBA. No assignment shall be
approved in violation or frustration of the Kansas Economic Growth Act, the mission of the KBA or any other applicable laws. 

13. Binding on Successors. This Agreement will be binding on any successors, heirs, and assigns of Grantee. 

14. Authority. Each party to this Agreement represents and warrants to the other party that the execution, delivery, and
performance of this Agreement by the party has been duly and validly authorized and approved by all necessary action of the party. This Agreement constitutes the legal, valid, and binding obligations of such party, enforceable against it in
accordance with its terms. 
 15. No Violation. Grantee represents and warrants to the KBA that the execution and
performance of this Agreement by Grantee will not constitute a violation of any law or any legal or contractual rights of any third party. 
 16. Governing Law. This Agreement will be governed by and construed in accordance with the laws of the State of Kansas, without regard to principles of conflicts of laws thereof. 

17. Notice. All notices or other communications required or permitted under this Agreement will be in writing and will be deemed
duly given (a) when delivered in person to the recipient party, (b) upon transmittal of a facsimile or email transmission to the recipient party at the facsimile number or email address designated below, with reasonable evidence of
successful transmission, or (c) three business days after being mailed by either registered or certified U.S. mail, return receipt requested, postage prepaid to the recipient party at the mailing address designated for the recipient party as
follows: 
  

			
	If to KBA:	  	If to Grantee:
		
	Kansas Bioscience Authority	  	Aratana Therapeutics, Inc.
	10900 S. Clay Blair Blvd	  	1901 Olathe Blvd.
	Olathe, KS 66061	  	Kansas City, KS 66103
	Telephone: (913) 397-8300	  	Telephone: 913-951-2132
		
	Contracts: Nancy R. Ruf	  	Contracts: David K. Rosen
	Email: ruf@kansasbioauthority.org	  	Email: drosen@aratanarx.com
		
	Technical: Tony Simpson	  	Technical: David K. Rosen
	Email: simpson@kansasbioauthority.orgn	  	Email: drosen@aratanarx.com

  
 6 

 This Agreement represents the entire understanding between the KBA and Grantee concerning
the Project and supersedes all prior and contemporaneous agreements and communications of the Parties, whether written or oral. 

This Agreement has been duly signed by authorized officers of each party. 

 

									
	GRANTEE:	 		 	KANSAS BIOSCIENCE AUTHORITY:
					
	By:	 	 /s/ David K. Rosen
	 		 	By:	 	 /s/ David Vranicar

					
	Name:	 	David K. Rosen	 		 	Name:	 	David Vranicar
	Title:	 	President and COO	 		 	Title:	 	President and CEO
	Date:	 	 10 April 2012
	 		 	Date:	 	 04/3/2012

  
 7 

 EXHIBIT A - Award Payment Request Form 

 

									
	Company Name:	  	  
	  		  	Date:	  	  

		  	(NOTE: name of the check payee)	  		  		  	
				
	Project Name:	  	 Aratana R&D Voucher
	  		  	KBA Grant #: 557

  

	1a.	Amount Requested: $              Milestone Number(s):
             

  

	1b.	Please circle CHECK or WIRE TRANSFER (Provide bank info for wire transfer - required for payments over $750,000) 

 

	2.	Describe the milestone(s) achieved for this payment request, and attach supporting documentation. 

 

	3.	Give a brief description of the status of the project. 

  

	4.	Detail all subsequent milestones for which you will be requesting payment (and give an approximate achievement date for each). 

 

	5.	Detail any new jobs created since the award date (provide supporting documentation, e.g., Employee Name or ID, Title and Hire Date). 

 

	6.	Detail any capital expenditures since the award date (provide supporting documentation) 

 

	7.	Detail any research dollars received since the award date (provide supporting documentation, e.g. Notice of Awards, Project Title, Amount, Project Period and
PI). 

  

	8.	Detail any investment capital received since the award date (provide supporting documentation, e.g. Cap Table). 

As a duly authorized official of
                                        , I
hereby attest that the information provided is a true and accurate representation of the information requested. 
  

			
	Name:	 	  

		
	Title:	 	  

		
	Address:	 	  

  
 8 

 EXHIBIT B – Budget 
 Aratana has budgeted $14.73 million for the R&D efforts associated with developing AT-001 and AT-002 to regulatory approval over 5 years. Of that total, approximately $6.56 million is budgeted for
AT-001, while the remaining $8.17 million is estimated to be spent to develop AT-002 across the three possible indications. 
 Over the next two
years, Aratana has identified $4.0 million of this development program that can be conducted in Kansas with the collaborators identified below and in Section 1. 
  

									
	 	  	2012 Product Development Budget	 
	 	  	Kansas Collaborators	 
	 Collaborator
	  	Product	  	 	  	Amount	 
	 Argenta
	  	AT-001	  		  	$	469,457	  
		  	AT-002	  		  	$	770,660	  
		  		  	Total	  	$	1,240,117	  
				
	 AlcheraBio
	  	AT-001	  		  	$	375,000	  
		  	AT-002	  		  	$	360,000	  
		  		  	Total	  	$	735,000	  
	 XenoMetrics
	  	AT-001	  		  	$	50,000	  
		  	AT-002	  		  	$	150,000	  
		  		  	Total	  	$	200,000	  
	 KCAS
	  	AT-002	  		  	$	99,000	  
		  		  	Total	  	$	99,000	  
		  	Total Project Expenses	  	$	2,274,117	  

 For work conducted beyond 2012, Aratana has indicated that approximately $2,000,000 of the Pivotal Safety and Efficacy
trial work will be conducted in 2012 in Kansas with Kansas collaborators. As part of the proposed milestones, KBA staff has included the submission of an updated work plan and budget for these studies as part of Milestone # 4 of this proposed
voucher. 
 Aratana has entered into Master Service Agreements with AlcheraBio, Xenometrics and Argenta. Specific scope of work
documents for the Argenta projects can be found in Appendix C and Appendix D of this document. Projects to be conducted by KCAS will be documented on individual work orders which will be provided to KBA as part of the Award Payment
process. 

  
 9 

 EXHIBIT C – Repayment Statute 

74-99b18 

Chapter 74.—STATE BOARDS, COMMISSIONS AND AUTHORITIES 
 Article 99b.—BIOSCIENCE AUTHORITY 
 74-99b18. Companies receiving authority
financing; repayment required, when. 
 Each bioscience company or qualified company receiving grants, awards, tax credits or
any other financial assistance, including financing for any bioscience development project, under the provisions of the bioscience authority act, the emerging industry investment act, the bioscience development financing act, the tax investment
incentive act, the bioscience research and development voucher program act, or the bioscience research matching funds act, shall repay such financial assistance to the authority, in the amount determined by the authority, if such bioscience company
or qualified company relocates operations, in which the authority invested, outside Kansas within 10 years after receiving such financial assistance. Each such bioscience company or qualified company shall enter into a repayment agreement with
the authority specifying the terms of such repayment obligation. 
 History: L. 2004, ch. 112, § 52; July 1. 

  
 10EX-10.18

 Exhibit 10.18 
 Execution Version 
 EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005

 This EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005 (this
“Agreement”) is entered into as of December 27, 2010 (the “Effective Date”) by and between Aratana Therapeutics Inc., a Delaware corporation having a place of business is 1901 Olathe Boulevard, Kansas
City, KS 66103 (“Licensee”) and RaQualia Pharma Inc., a Japanese corporation having a place of business at 5-2 Taketoyo, Aichi 470-2341, Japan (“Licensor”). 

RECITALS 
 WHEREAS, Licensor owns certain rights and technology pertaining to a ghrelin agonist (Capromorelin) for treating anorexia, cachexia and unintended weight loss, including all analogs,
formulations thereto, and related back-up programs thereto (collectively, “RQ-00000005 Technology”); and 

WHEREAS, Licensee desires to receive an exclusive worldwide license to RQ-00000005 Technology, and Licensor is
willing to grant such license to Licensee under the terms and conditions provided herein. 
 NOW,
THEREFORE, in consideration of the mutual covenants set forth herein and for other consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 

AGREEMENT 

1. DEFINITIONS. As used in this Agreement: 
 1.1 “Target Animal Safety Study” means the pivotal regulatory study to assess animal safety in cats or dogs. 

1.2 “Affiliate” of a party means any person or entity, which controls, is controlled by, or is under common
control with such party, where “control” means ownership of fifty percent (50%) or more of the outstanding voting securities. 
 1.3 “Combination Product” means any pharmaceutical drug which consists of a Royalty-Bearing Product and other active compounds and/or active ingredients, where such combination of
the Royalty-Bearing Product with the other active compound and/or active ingredient is not covered by any Licensed Patent. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

 1.4 “First Commercial Sale” shall mean, with respect to any
Royalty-Bearing Product, the first sale for end use or consumption of such Royalty-Bearing Product in a country after the governing health regulatory authority of such country has granted regulatory approval of such Royalty-Bearing Product.

 1.5 “Improvements” means any upgrade, enhancement, modification, alteration, improvement,
development, or other change made to the Licensed Know How or the inventions disclosed in the Licensed Patents during the term of this Agreement. 
 1.6 “Licensed Know-How” shall mean unpatented information to the extent owned or controlled by Licensor as of the Effective Date associated with the Licensed Patents or related to
RQ-00000005 Technology, including but not limited to research and development information, trade secrets, engineering, scientific, and practical information, data, formulas, formulations, APIs, analogs, back-up programs, information about qualities,
uses, test methods and results, information about materials, compositions and sources, and drawings, specifications, laboratory notebooks, work product and other relevant writings, in each case, which is necessary or desirable for the practice of
the Licensed Patents or the RQ-00000005 Technology. 
 1.7 “Licensed Patents” means (i) the patents
listed in Exhibit A; (ii) any patent or patent application that claims priority to and is a divisional, continuation, continuation-in-part, reissue, renewal, reexamination, substitution or extension of any patent application
identified in (i); (iii) any patents issuing on any of the patent applications identified in (i) or (ii), including any reissues, renewals, reexaminations, substitutions or extensions thereof; (iv) any foreign counterpart
(including PCTs) of any of the patents or patent applications identified in (i), (ii) or (iii); and (v) any other patent or patent application owned or controlled by Licensor now or during the term of this Agreement pertaining to
RQ-00000005 Technology or Licensor Improvements. 
 1.8 “Licensed Process” means any process that would
infringe one or more Valid Claims of a Licensed Patent, but for the license granted in Section 2.1. 
 1.9
“Licensed Products” means any product in the Licensee Field of Use (i) that would infringe one or more Valid Claims of a Licensed Patent, but for the license granted in Section 2.1 or (ii) is manufactured using a
Licensed Process or (iii) when used, practices a Licensed Process. 
 1.10 “Licensee Field of Use”
means the field of animal health. 
 1.11 “Licensee Improvements” means Improvements created, conceived,
or reduced to practice by or for Licensee. 
 1.12 “Licensor Field of Use” means the field of human
health. 
 1.13 “Licensor Improvements” means Improvements created, conceived, or reduced to practice by
or for Licensor. 
 1.14 “NADA” means a new animal drug application as prescribed by applicable U.S.
food and drug administration (FDA) regulations, or any corresponding foreign statutes, rules or regulations. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

2 

 1.15 “Net Sales Revenue” means [***]. 

1.16 “Royalty-Bearing Product” means a pharmaceutical drug that, absent the license granted in Section 2.1,
the sale of which would infringe one or more Valid Claims of an issued Licensed Patent in force in the country in which such drug is sold. 
 1.17 “Subsidiary” means any entity which is controlled by a party, either directly or indirectly, where “control” means ownership of fifty percent (50%) or more of
the outstanding voting securities. 
 1.18 “Valid Claim” means a claim of an issued or granted Licensed
Patent in any country that has not expired or lapsed, been abandoned or cancelled, or held or declared invalid or unenforceable. 
 2.
LICENSE 
 2.1 Patent License Grant. Licensor hereby grants to Licensee a worldwide, exclusive (without
any reservation of rights by Licensor) license under the Licensed Patents during the term of this Agreement, to: (i) use, develop, make, have made, sell, offer to sell, import, export, lease, or otherwise dispose of any Licensed Product;
(ii) use any method or process in manufacturing the Licensed Products; (iii) use and perform any Licensed Processes; and (iv) to otherwise practice the claimed inventions pertaining to RQ-00000005 Technology in the Licensee Field of
Use. 
 2.2 Know-How License Grant. Licensor hereby grants to Licensee a worldwide, exclusive (without any reservation of
rights by Licensor) license under the Licensed Patents during the term of this Agreement to use the Licensed Know-How in connection with any development, manufacture, sale, importation, exportation, lease or disposal of any Licensed Product or
performance of any Licensed Process in the Licensee Field of Use. 
 2.3 Technology Transfer. Within [***] days of the
Effective Date, Licensor shall provide Licensee, at no cost, copies of all documents, materials, data sheets, test results, analyses, formulations, compositions and all other tangible embodiments of the Licensed Know-How and Licensed Patents
(“Material”). Licensor shall make available to Licensee, upon reasonable request, employees and agents of Licensor to facilitate the technology transfer of the Know-How and to respond to Licensee inquiries pertaining to the Licensed
Know-How and Licensed Patents to facilitate Licensee’s full use, enjoyment, and exploitation of the licenses granted herein. 
 2.4 Sublicense. The licenses granted in Sections 2.1 and 2.2 include the right of Licensee to sublicense any and all of the licensed rights to one or more tiers of sublicenses including but not
limited to its Affiliates. All sublicenses granted to third parties will be pursuant to written agreement that are in accordance with and no broader than the terms of this Agreement. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

3 

 3. FEES, REPORTS, AND AUDIT 

3.1 Initial Licensee Fees and Royalty 
 (a) Initial License Fees. In consideration for the licenses to the Licensed Patents, Licensed Know-How, and Licensor Improvements, [***] days after the Effective Date, Licensee will pay Licensor a
license fee of [***] US Dollars ([***]). 
 (b) Sales Royalty. Licensee will pay to Licensor a royalty in the amount
of [***] percent ([***]%) of Net Sales Revenue received by Licensee for the sale of the Royalty Bearing Products in countries where there are Valid Claims of the Licensed Patents until such Licensed Patents have expired or been abandoned. If
Licensee sublicenses the Licensed Patents to a third party sublicensee, Licensee will pay to Licensor a royalty in the amount equal to [***] percent ([***]%) of the royalty paid by such sublicensee to Licensee based on the sale of the Royalty
Bearing Products in countries where there are Valid Claims of the Licensed Patents until such Licensed Patents have expired or been abandoned, but in no event shall the royalty paid to Licensor be less than [***] percent ([***]%) of the Net
Sales Revenue of such third party sublicensee. Royalty payments shall be due on a [***] basis within [***] days after [***]. 

3.2 Milestone Fees. Except with respect milestone fees triggered upon a NADA filing, within [***] days after the occurrence of the
following milestones, Licensee will pay Licensor the corresponding one-time milestone fees provided below. With respect to any milestone fee based on a NADA filing, Licensee will pay Licensor the corresponding one-time milestone fee provided below
for such NADA filing within [***] months after such NADA filing. For avoidance of doubt, the parties agree that Licensee’s obligation to pay each milestone fee referenced below is a one-time obligation even if the applicable milestone event
occurs more than once. 
  

			
	 Milestone
	  	Milestone Fee
	 [***]
	  	[***] US Dollars ($[***])
	 [***]
	  	[***] US Dollars ($[***])
	 [***]
	  	[***] US Dollars ($[***])
	 [***]
	  	[***] US Dollars ($[***])
	 [***]
	  	[***] US Dollars ($[***])

 3.3 Third Party Patent Rights. In the event it becomes necessary for Licensee or its sublicensee
to license patent rights owned by a third party to use, develop, make, have made, sell, offer to sell, import, export, lease, or otherwise dispose of any Royalty-Bearing Product, then Licensee or its sublicensee, as applicable, shall have the right
to obtain a license from such third party and to credit [***] percent ([***]%) of any payment owed to such third party under such license against the royalty payable to Licensor under Section 3.1 above on a going forward basis. No such
amounts deducted shall reduce royalties paid to Licensor by more than [***] percent ([***]%); provided, however, that amounts not deducted because of this limit may be carried forward and applied to future royalties paid, subject to the [***]
percent ([***]%) floor. 
 3.4 Reports. Along with each royalty payment, Licensee will provide a statement showing
the quantity of Royalty-Bearing Products sold or transferred during the preceding [***] and a calculation of the royalties accrued during such quarter, provided that Licensee shall provide an estimated royalty report within [***] days after the end
of such calendar [***]. Licensor will treat these statement as Confidential Information of Licensee, will protect it from unauthorized use, access or disclosure in the same manner as Licensor protects its own confidential or proprietary information
of similar nature and with no less than reasonable care, and will disclose it only to the employees or agents of Licensor who have a need to know such information for purpose of this Agreement and who are under a duty of confidentiality no less
restrictive than Licensor’s duties hereunder. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

4 

 3.5 Audit Rights. Licensor will have the right to request an audit of the books and
records of Licensee directly relating to the royalty payments owed during the last [***] months for the sole purpose of verifying the amounts due and payable under this Agreement, not more than [***] per calendar year upon providing at least [***]
weeks prior written notice to Licensee. All such audits will be conducted during reasonable business hours of Licensee, in a manner that does not unreasonably interfere with such entity’s normal business activities and will be conducted by a
certified public accountant or equivalent chosen by Licensor (the “Auditor”) and reasonably acceptable to Licensee. Except for the statement of royalty payments due, the Auditor will not disclose any information learned during the
audit to Licensor, and all such information shall be considered the Confidential Information of Licensee. The audit will be conducted at Licensor’s expense, except if the audit shows that amount of royalty payments due to Licensor is greater
than [***] percent ([***]%) of the total royalty paid to Licensor for the immediately preceding calendar year, the Licensee or sublicensee will pay for the cost and expense of such audit without undue delay. 

3.6 Taxes. Licensor shall be responsible for all sales, use, VAT and other taxes (including taxes based on Licensor’s net
income), fees, duties and governmental charges, and any related penalties and interests, arising from the payment of any license fees and royalties to Licensor hereunder. 
 4. DUE DILIGENCE IN COMMERCIALIZATION. Licensee shall use commercially reasonable efforts to bring Licensed Products to market through a
diligent program for the development, regulatory approval, and commercialization of Licensed Products to generate Net Sales Revenue during the term of this Agreement. Licensee shall be responsible for all reasonable expenses which may be incurred in
connection with regulatory filings and clinical trials in support of market approval for the Licensed Products. Licensee shall provide Licensor with a progress report on [***] basis, beginning on the [***] anniversary of the Effective Date, setting
forth Licensee’s development, regulatory, clinical, and commercialization efforts regarding the Licensed Products under this Agreement. 

5. DEVELOPMENT & ADVERSE EVENT 

5.1 Development Plan. Within [***] days following the Effective Date, Licensee shall submit to Licensor a plan and related and
estimated timetable for studies and other tests with respect to the development of Licensed Products in the United States and European Union and such plan and timetable being hereinafter referred to as “Development Plan” and attached to
this Agreement as Exhibit B, upon completion. During the term of this Agreement, Licensee shall report to Licensor significant modification thereof. 
 5.2 Development Work. Licensee shall be responsible for all reasonable expenses which may be incurred in connection with regulatory filings and pre-clinical and clinical studies in support of
market approval for the Licensed Products. Licensee shall use commercially reasonably efforts to carry out such pre-clinical and clinical studies or tests in substantial accordance with the Development Plan or any amendment thereto. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

5 

 5.3 Adverse Event Reporting. In the event that any serious accidents, such as adverse
drug reactions, occur during the development of the Licensed Product, both parties shall immediately notify each other of such events together with relevant information that each party may be required to disclose to meet all periodic and annual
safety regulatory requirements imposed by the regulatory authorities, and shall discuss the solutions in good faith and take all the necessary measures immediately. 
 6. IMPROVEMENTS 
 6.1 Disclosure. Licensor and
Licensee shall meet at least [***] during the term of this Agreement at a time and place mutually agreed upon by the parties to disclose Licensor and Licensee Improvements. At each meeting, each party will provide the other party with a brief
written description of any Improvements of such party created, conceived, or reduced to practice since the last meeting, and will provide the other party with a list and description of all patent applications pertaining to the Improvements filed
since the last meeting. 
 6.2 License from Licensor. Licensee shall automatically receive a license to all Licensor
Improvements pursuant to the licenses granted in Section 2.1 and Section 2.2. All Licensor Improvements shall remain owned by Licensor. For avoidance of doubt, any patents and patent applications that claim the RQ-00000005 Technology or
the Licensed Products filed by or on behalf of Licensor or any of its Subsidiaries will be considered Licensor Improvements. 

6.3 License from Licensee. Licensee shall grant to Licensor a license to the Licensee Improvements in the Licensor Field of Use
pursuant to a license agreement to be entered into, which will include terms substantially equivalent to those provided in this Agreement. All such Licensee Improvements shall remain owned by Licensee. For avoidance of doubt, any patents and patent
applications that claim the RQ-00000005 Technology or the Licensed Products filed by or on behalf of Licensee or any of its Subsidiaries will be considered Licensee Improvements. 
 7. SUPPLY 
 7.1 Clinical Supply. Licensor and Licensee
will use good faith to negotiate and enter into a non-exclusive clinical supply agreement for the API and Licensed Products for clinical use (the “Clinical Supply Agreement”) within [***] days of the Effective Date. The Clinical
Supply Agreement shall, at a minimum, (i) provide for the supply of API as being on the effective date of the Agreement, and (ii) include customary representations and warranties and indemnifications. Initially, Licensee will order [***]
of API without any compensation to Licensor. For future clinical supplies, if Licensor or any of its other licensees is using a third party manufacturer for API or Licensed Product tablets, Licensor shall allow Licensee to get supply of such API or
tablets for Licensee from such third party manufacturer, including at any prices negotiated by Licensor. The Clinical Supply Agreement will contemplate a price of API and/or tablets which shall be no greater than Licensor’s cost of
manufacturing such API or tablets. However, the cost for the required analytical works and the Licensor’s cost of handling solely for Licensee shall be charged to Licensee. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

6 

 7.2 Commercial Supply Agreement. For avoidance of doubt, Licensee shall be entitled
to purchase API’s and License Products directly from Licensor or use any third party manufacturers to manufacture API’s and Licensed Products on behalf of Licensee. Upon Licensee’s request, Licensor shall provide such third party
manufacturers with all available data, quality control information, manufacturing specifications and information, and all other material and information reasonably needed by such third party manufacturers to manufacture commercially suitable
Licensed Products for Licensee. 
 8. PROSECUTION AND ENFORCEMENT 

8.1 Prosecution. Licensor will have the right to control filing, prosecution, and maintenance of the Licensed Patents, including
any patents and applications based on Licensor Improvements, at Licensor’s expense. Licensee will have the right to control filing, prosecution, and maintenance of patents and applications based on Licensee Improvements, at Licensee’s
expense. The party controlling the filing, prosecution, and maintenance of an invention is referred to herein as the “Prosecuting Party”, while the other party is referred to herein as the “Non-Prosecuting Party”.
The Non-Prosecuting Party shall have the right to participate, at its cost and expense, in the filing and prosecution activities of the Prosecuting Party. The Prosecuting Party will notify the Non-Prosecuting Party periodically of the status of any
pending cases included in the patents or patent applications licensed to the other party, including any office actions, notice of allowance, and required filings or payments concerning such patents and patent applications. The Non-Prosecuting Party
will have the opportunity to comment on any response to office actions or amendments to claims prior to their filing. The Non-Prosecuting Party will have the right to inspect the records kept by the Prosecuting Party and its patent counsel
pertaining to the patents and patent applications licensed to the Non-Prosecuting Party. The Non-Prosecuting Party will, at the Prosecuting Party’s request and expense, sign all instruments and documents, including powers of attorney, necessary
to effectuate the purpose of this Section 8.1 and provide any other reasonably necessary assistance requested by the Prosecuting Party. If the Prosecuting Party elects to abandon any application or patent licensed to the other party, the
Non-Prosecuting Party will have the right to continue prosecution or maintenance of such application or patent at the Non-Prosecuting Party’s sole expense. 
 8.2 Enforcement. Each party will promptly notify the other party upon becoming aware of any known or suspected infringement of any patents licensed to the other party under this Agreement or the
license agreement referenced in Section 5.3. Such notice will include the identity of the party or parties known or suspected to have infringed the licensed patent and any available information that is relevant to such infringement. The party
who is the exclusive licensee of such licensed patent within the field of use subject to the infringement action (the “Enforcing Party”) will retain sole control over enforcement and defense of the patent against such third party
infringers. If the Enforcing Party files or defends any claim, suit, or action (a “Claim”) against any third party based on any licensed patent, the other party (the “Non-Enforcing Party”) will cooperate with the
Enforcing Party, at the Enforcing Party’s request, in enforcing or defending such Claim, including joining the Enforcing Party as a party to such suit or action to the extent necessary to establish standing. The Enforcing Party will be
responsible 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

7 

 
for all costs, expenses, and legal fees (collectively “Costs”) incurred by the Non-Enforcing party in connection with any Claim. The Enforcing Party will be entitled to all
damages awarded as a result of or agreed to in a monetary settlement of any Claim, subject to any royalty payment obligation. Nothing contained in this Section will obligate the Enforcing Party to enforce or defend any patent licensed to it.

 9. CONFIDENTIALITY 
 9.1 Confidential Information. During the term of this Agreement, each party (the “Receiving Party”) may be provided with, have access to, or otherwise learn confidential and/or
proprietary information of the other party (the “Disclosing Party”) (including certain information and materials concerning the Disclosing Party’s business, plans, customers, technology, and products) that is of substantial
value to the Disclosing Party, and which is identified as confidential at the time of disclosure or which should reasonably be considered, under the circumstances of its disclosure, to be confidential to the Disclosing Party (“Confidential
Information”). 
 9.2 Confidentiality Obligations. All Confidential Information remains the property of the
Disclosing Party. The Receiving Party may disclose the Confidential Information of the Disclosing Party only to its employees and contractors who need to know the Confidential Information for purposes of performing under this Agreement and who are
bound by the Receiving Party’s standard employee or contractor (as applicable) confidentiality agreements. The Receiving Party will not use the Confidential Information without the Disclosing Party’s prior written consent except in
performance under this Agreement. The Receiving Party will take measures to maintain the confidentiality of the Confidential Information equivalent to those measures the Receiving Party uses to maintain the confidentiality of its own confidential
information of like importance but in no event less than reasonable measures. The Receiving Party will give immediate notice to the Disclosing Party of any unauthorized use or disclosure of the Confidential Information that comes to the attention of
the Receiving Party’s senior management and agrees to assist the Disclosing Party in remedying such unauthorized use or disclosure. 
 9.3 Exceptions. The confidentiality obligations do not extend to Confidential Information which: (i) becomes part of the public domain without the fault of the Receiving Party; (ii) is
rightfully obtained by the Receiving Party from a third party with the right to transfer such information without obligation of confidentiality; (iii) is independently developed by the Receiving Party without reference to or use of the
Disclosing Party’s Confidential Information, as evidenced by written records; or (iv) was lawfully in the possession of the Receiving Party at the time of disclosure, without restriction on disclosure, as evidenced by written records. In
addition, the Receiving Party may disclose Confidential Information of the Disclosing Party as may be required by law, a court order, or a governmental agency with jurisdiction, provided that before making such a disclosure the Receiving Party first
notifies the Disclosing Party promptly and in writing and cooperates with the Disclosing Party, at the Disclosing Party’s reasonable request and expense, in any lawful action to contest or limit the scope of such required disclosure. In
addition, Licensee may disclose any Materials provided by Licensor to Licensee’s contract manufacturers, employees, agents and third parties without restriction, even if such Materials contain Confidential Information of Licensor. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

8 

 9.4 Return of Confidential Information. Upon termination (but not expiration) of this
Agreement, the Receiving Party will return to the Disclosing Party or destroy all tangible copies of Confidential Information of the Disclosing Party, which the Receiving Party no longer has the right to use, in the Receiving Party’s possession
or control and will erase from its computer systems all electronic copies thereof. 
 9.5 Confidentiality of the
Agreement. Neither party will disclose any terms or conditions of this Agreement to any third party, without the prior written consent of the other party, except: (i) as required by law; (ii) to its attorneys, accountants, and other
professional advisors under a duty of confidentiality; or (iii) to a third party under a duty of confidentiality in connection with financing or a proposed merger or a proposed sale of all or part of such party’s business which relates to
this Agreement. 
 9.6 Survival of Obligations. Licensee’s and Licensor’s respective obligation under this
Section 8 shall survive any termination or expiration of this Agreement and shall extend to the earlier of such time as the Confidential Information is in the public domain or [***] years following termination or expiration of this Agreement.

 10. REPRESENTATIONS AND WARRANTIES 

10.1 Mutual Representations and Warranties. Each party represents and warrants that it has full right, power, and authority to
enter into this Agreement and to perform its obligations and duties under this Agreement, and that the performance of such obligations and duties does not and will not conflict with or result in a breach of any other agreements of such party or any
judgment, order, or decree by which such party is bound. 
 10.2 Representations and Warranties By Licensor. Licensor
represents and warrants that: 
 (a) it exclusively owns and has full right, power, and authority to license the Licensed
Patents and the Licensed Know-How to Licensee; 
 (b) it has not granted or will grant during the term of this Agreement
any security interest, option, lien, license, or encumbrance of any nature with respect to any Licensed Patent or Licensed Know-How which would conflict with the license granted to Licensee under this Agreement; 

(c) to the best knowledge of Licensor, all of the Licensed Patents that have issued are valid and enforceable, and no proceeding is
pending or to the best knowledge of Licensor, threatened, nor has any claim been made, which challenges or challenged the legality, validity, or enforceability of any Licensed Patent; 

(d) all maintenance fees, annuity payments, and similar payments relating to the Licensed Patents have been made and will be made
in a timely manner during the term of this Agreement; and 
 (e) to the knowledge of Licensor, using, making, selling, or
importing a Licensed Product or performing a Licensed Process shall not infringe, directly or indirectly, any patent or other intellectual property rights of any third party. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

9 

 10.3 Limitation of Liability. EXCEPT FOR
BREACH OR REPRESENTATIONS OF WARRANTIES PROVIDED IN THIS AGREEMENT, IN NO
EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY OR ANY
THIRD PARTY FOR ANY CONSEQUENTIAL, INDIRECT, PUNITIVE, EXEMPLARY, SPECIAL OR
INCIDENTAL DAMAGES, INCLUDING ANY LOST DATA AND LOST PROFITS, ARISING FROM
OR RELATING TO THIS AGREEMENT, THE LICENSED PATENTS, THE LICENSED
KNOW-HOW, OR IMPROVEMENTS. LICENSEE’S TOTAL CUMULATIVE LIABILITY IN CONNECTION
WITH THIS AGREEMENT, THE LICENSED PATENTS, THE LICENSED KNOW-HOW, OR
IMPROVEMENTS, WHETHER IN CONTRACT OR TORT OR OTHERWISE, WILL NOT EXCEED
THE TOTAL AMOUNT OF FEES AND ROYALTIES PAID TO LICENSOR UNDER THIS
AGREEMENT DURING THE [***] MONTHS PRECEDING THE CLAIM. 
 11. INDEMNIFICATION 
 11.1 By Licensor. Licensor will
defend, indemnify, and hold Licensee, Licensee’s Affiliates, and their directors, officers, employees, and agents harmless from and against any and all claims, losses, liabilities, damages, costs, and expenses (including attorneys’ fees,
expert witness fees, and court costs) directly or indirectly arising from or relating to: (i) any product liability claims based on the manufacture, marketing, promotion, sale, distribution, or use of any Licensed Products by Licensor or its
customers; and (ii) any negligence or willful misconduct by Licensor or its directors, officers, employees, or agents in the performance of this Agreement or in connection with manufacture, marketing, promotion, sale, distribution, or use of
Licensed Products. In addition, Licensor will defend, indemnify, and hold Licensee, its Affiliates, sublicensees, and each of their customers, directors, officers, employees, and agents harmless from and against any and all claims, losses,
liabilities, damages, costs, and expenses (including attorneys’ fees, expert witness fees, and court costs) directly or indirectly arising from or relating to any allegation that manufacture, use, offer for sale, sale, or importation of any
Licensed Product or use of any Licensed Know-How as permitted under this Agreement infringes any third party’s intellectual property rights. 
 11.2 By Licensee. Licensee will defend, indemnify, and hold Licensor, Licensor’s Affiliates, and their directors, officers, employees, and agents harmless from and against any and all claims,
losses, liabilities, damages, costs, and expenses (including attorneys’ fees, expert witness fees, and court costs) directly or indirectly arising from or relating to (i) any product liability claims based on the manufacture, marketing,
promotion, sale, distribution, or use of any Licensed Products by Licensee or its customers, or (ii) any negligence or willful misconduct by Licensee or its directors, officers, employees, or agents in the performance of this Agreement or in
connection with manufacture, marketing, promotion, sale, distribution, or use of Licensed Products. 
 11.3 Indemnity
Conditions. A party’s obligation to indemnify as provided in this Agreement is conditioned upon the indemnified party promptly notifying the indemnifying party in writing within a reasonable period of time of any and all claims for which
the indemnified party is entitled to indemnification, giving the indemnifying party sole control of the defense 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

10 

 
thereof and any related settlement negotiations, and indemnified party cooperating and, at indemnifying party’s request and expense, assisting in such defense. The indemnified party may
participate in the defense of the claim at its own expense with counsel of its own choosing. The indemnifying party may not settle any such claim without the indemnified party’s prior written consent. 

12. PUBLICITY 
 12.1 Public Announcements. Except as required by applicable laws, neither Licensor nor Licensee shall make any public announcement of any information regarding this Agreement (including without
limitation its execution and terms), the Licensed Products or development or commercialization activities under this Agreement without the prior written approval of the other party, which approval shall not be withheld unreasonably. Once any
statement is approved for disclosure by the parties or information is otherwise made public in accordance with the preceding sentence, either party may make a subsequent public disclosure of the contents of such statement without further approval of
the other party. Notwithstanding the foregoing, either party may disclose the terms of this Agreement (i) as required by law; (ii) to its attorneys, accountants, and other professional advisors under a duty of confidentiality;
(iii) to a third party under a duty of confidentiality in connection with any proposed or actual financing or investment, or a proposed or actual merger or sale of all or part of such party’s business relating to this Agreement.

 13. TERM AND TERMINATION 

13.1 Term. This Agreement will take effect on the Effective Date, and remain in effect until terminated as provided in
Section 13.2 or 10.3. 
 13.2 Termination for Good Cause. Licensor may terminate this Agreement by giving a written
notice of termination to Licensee if Licensee fails to pay any undisputed fees owed under this Agreement and does not cure such breach within [***] days after a written notice is given to Licensee requesting that such breach be cured. Once all
Licensed Patents have expired or have been abandoned, the licenses granted herein will be deemed fully-paid and irrevocable. 

13.3 Termination for Convenience. At any time during the term of this Agreement, Licensee may terminate this entire Agreement or
terminate any license granted herein on a patent-by-patent basis or country-by-country basis for any reason or no reason by giving Licensor a written notice of termination. Termination will be effective [***] days after the date of the notice of
termination. 
 13.4 Effect of Termination. On the effective date of termination of this Agreement (the
“Termination Date”), all licenses granted by Licensor to Licensee under this Agreement will be revoked and Licensee will cease all further use, manufacture, sale, or importation of the Licensed Products and use of the Licensed
Processes, except as provided in this Section. Licensee may complete and sell any work-in-progress and inventory of the Licensed Products that exist as of the Termination Date for a period of [***] months after the Termination Date, provided that
Licensee pays Licensor the applicable running royalty or other amounts due on such sales of Royalty-Bearing Products in accordance with Section 3.1. All sublicenses granted prior to the Termination Date will remain in place provided that the
sublicensees are in compliance with the terms and conditions of the sublicense agreements. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

11 

 13.5 Survival. Upon termination or expiration of this Agreement, Sections 1, 9, 10.3,
11, and 13.4 will survive. 
 14. GENERAL 
 14.1 Notice. Any notice, approval, authorization, consent, or other communication required or permitted to be delivered to either party under this Agreement must be in writing and will be deemed
properly delivered, given, and received (i) when delivered by hand, or (ii) three (3) business days after delivery by international courier or express delivery service (return receipt requested). All notices shall be sent to address
set forth below (or to such other address as may be designated by a party by giving written notice to the other party pursuant to this Section 11.1): 
  

			
	If to Licensor, to:	  	If to Licensee, to:
		
	RaQualia Pharma, Inc.	  	Aratana Therapeutics LLC
	5-2 Taketoyo, Aichi 470-2341	  	1901 Olathe Boulevard
	Japan	  	Kansas City, KS 66103
	Attention: President	  	USA
	Phone No.:	  	Attention:
		  	Phone No.:

 14.2 Governing Law; Arbitration. This Agreement will be construed in accordance with and governed
in all respects by the laws of the State of New York, USA. Any dispute, controversy or claim arising out of or in connection with this Agreement, or breach, termination or invalidity thereof, shall be settled by arbitration in accordance with the
commercial arbitration rules of the International Chamber of Commerce (“ICC”). The arbitral tribunal shall be composed of three arbitrators, one to be appointed by Licensor and one to be appointed by Licensee and the chairman to be
appointed by the two arbitrators. If the two aforementioned parties have not appointed their arbitrators within [***] weeks from the request of the other party, or the two arbitrators have not agreed on the chairman within three weeks after their
appointment, the ICC shall appoint the arbitrator or the chairman, as the case may be. In the event arbitration is requested by Licensor, the place of arbitration shall be [***]; in the event arbitration is requested by Licensee, the place of
arbitration shall be [***]. The arbitration proceedings will be conducted in English. The results of the arbitration procedure will be considered Confidential Information of the parties. Any arbitration decision rendered will be final and binding,
and judgment thereon may be entered in any court of competent jurisdiction. Notwithstanding this Section, neither party will be required to arbitrate any dispute or controversy relating to any actual or threatened unauthorized use or disclosure of
its intellectual property or confidential information. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

12 

 14.3 Assignment. Upon written notice to Licensor, Licensee may assign this entire
Agreement or any of its rights hereunder, without Licensor’s consent, (i) to any of Licensee’s Affiliates; and (ii) to a third party in connection with .a merger, change in control, or sale of all or substantially all of the
assets of Licensee pertaining to this Agreement. This Agreement will be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns. 

14.4 Remedies. The rights and remedies of the parties will be cumulative (and not alternative). If any legal action is brought to
enforce this Agreement, the prevailing party will be addition to any other relief it may receive. 
 14.5 Waiver. All
waivers must be in writing and signed by an authorized representative of the party to be charged. Any waiver or failure to enforce any provision of this Agreement on one occasion will not be deemed a waiver of any other provision or of such
provision on any other occasion. 
 14.6 Severability. If any provision of this Agreement is unenforceable, such
provision will be changed and interpreted to accomplish the objectives of such provision to the greatest extent possible under applicable law and the remaining provisions will continue in full force and effect. 

14.7 Independent Contractors. This Agreement is not intended to establish any partnership, joint venture, employment, or other
relationship between the parties except that of independent contractors. 
 14.8 Construction. The section headings in
this Agreement are for convenience of reference only, will not be deemed to be a part of this Agreement, and will not be referred to in connection with the construction or interpretation of this Agreement. Any rule of construction to the effect that
ambiguities are to be resolved against the drafting party will not be applied in the construction or interpretation of this Agreement. As used in this Agreement, the words “include” and “including,” and variations thereof, will
not be deemed to be terms of limitation, but rather will be deemed to be followed by the words “without limitation.” All references in this Agreement to “Sections” are intended to refer to Sections of this Agreement. 

14.9 Counterparts. This Agreement may be executed in several counterparts, each of which will constitute an original and all of
which, when taken together, will constitute one agreement. 
 14.10 English Language. This Agreement has been prepared in
the English language and the English language shall control its interpretation. In addition, all notices required or permitted to be given hereunder, an all written, electronic, or other communications between the parties regarding this Agreement
shall be in the English language 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

13 

 14.11 Entire Agreement. This Agreement, along with the Exhibits hereto, set forth the
entire understanding of the parties relating to the subject matter hereof and supersedes all prior agreements and understandings between the parties relating to the subject matter hereof. This Agreement may not be amended, modified, altered, or
supplemented other than by means of a written instrument duly executed and delivered on behalf of both parties. 
 14.12
Bankruptcy. Licensor agrees that if Licensor, as a debtor in possession or a trustee in bankruptcy rejects this Agreement, Licensee may elect to retain its rights under this Agreement. Upon written request of Licensee to Licensor or the
bankruptcy trustee, Licensor or such bankruptcy trustee will not interfere with the rights of Licensee as provided in this Agreement. 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

14 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first
above written. 
  

									
	RaQualia Pharma Inc.	 		 	Aratana Therapeutics Inc.
					
	By: 	 	/s/ Atsushi Nagahisa	 		 	By: 	 	/s/ David K. Rosen
	Name: Atsushi Nagahisa	 		 	Name: David K. Rosen
	Title: President & CEO	 		 	Title: President
			
	Date: December 21, 2010	 		 	Date: December 27, 2010

 [SIGNATURE PAGE TO EXCLUSIVE IP LICENSE AGREEMENT FOR RQ-00000005] 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

15 

 EXHIBIT A 

LICENSED PATENTS 
 Title : [***] 
 Inventors : [***] 

 

					
	 Country
	  	Application Number	 	Patent Number
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

 Title : [***] 
 Inventors : [***] 
  

					
	 Country
	  	Application Number	 	Patent Number
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

16 

					
	 Country
	  	Application Number	 	Patent Number
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

 Title : [***] 
 Inventors : [***] 
  

					
	 Country
	  	Application Number	 	Patent Number
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

17 

 Title : [***] 
 Inventors : [***] 
  

					
	 Country
	  	Application Number	 	Patent Number
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	
	 [***]
	  	[***]	 	[***]
	 [***]
	  	[***]	 	[***]

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

18 

 EXHIBIT B 

DEVELOPMENT PLAN 
 (to be attached upon its completion) 

  

	[***]	Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested
with respect to the omitted portions. 

  

19

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]